Cyclosporine Soft Capsules

Cyclosporine is a new type of T lymphocyte regulator that can specifically inhibit the activity of helper T lymphocytes, but does not inhibit T lymphocytes, but promotes their proliferation. This product can also inhibit the activity of B lymphocytes: this product can also selectively inhibit interleukin-2 and interferon-β secreted by T lymphocytes, and can also inhibit interleukin-1 secreted by monocytes and phagocytes. While significantly inhibiting host cell immunity, it also has an inhibitory effect on humoral immunity. It can inhibit the production of anti-graft antibodies in the body, and thus has an anti-rejection effect. This product does not affect the function of phagocytes and does not produce obvious bone marrow suppression.

Cyclosporine.

This product is a soft capsule, and the contents are light yellow or yellow oily liquid.

It is suitable for preventing rejection reactions of allogeneic kidney, liver, heart, bone marrow and other organs or tissues transplanted, and is also suitable for preventing and treating graft-versus-host reactions during bone marrow transplantation. This product is often used in combination with immunosuppressants such as adrenocortical hormones to improve the efficacy. In recent years, there have been reports of trials for the treatment of uveitis, severe aplastic anemia, refractory autoimmune thrombocytopenic purpura, psoriasis, refractory lupus nephritis, etc.

Common oral dosage for adults: The initial dose is 12-15 mg/kg per day based on body weight, and the dose is gradually reduced after 1-2 weeks, generally reducing 5% of the initial dose each week, and the maintenance dose is about 5-10 mg/kg per day. For patients undergoing transplantation, the drug is administered 4-12 hours before transplantation.

1. Common gastrointestinal reactions include anorexia, nausea, vomiting, gingival hyperplasia with bleeding, pain, and about 1/3 of the users have nephrotoxicity, which may cause renal impairment such as increased serum creatinine and urea nitrogen, decreased glomerular filtration rate, and hypertension. Gingival hyperplasia generally disappears 6 months after discontinuation of the drug. Chronic, progressive nephrotoxicity occurs more than 12 months after treatment. 2. Uncommon convulsions may be caused by the toxicity of this product to the kidney and hypomagnesemia. In addition, this product can also cause increased aminotransferase, cholestasis, hyperbilirubinemia, hyperglycemia, hirsutism, hand tremor, hyperuricemia with thrombocytopenia, microangiopathic hemolytic anemia, paresthesia of the limbs, painful cramps of the lower limbs, etc. In addition, there are reports that this product can promote ADP-induced platelet aggregation, increase the release of thromboxane A2 and the generation of thrombin, enhance the activity of factor VII, reduce the production of prostacyclin, and induce thrombosis. 3. Rare adverse reactions include allergic reactions, pancreatitis, leukopenia, Raynaud's syndrome, diabetes, hematuria, etc. (Allergic reactions generally only occur in patients who are given the drug intravenously, manifested as redness of the face and neck, asthma, shortness of breath, etc.) Most serious adverse reactions are related to excessive dosage. The method to prevent reactions is to regularly monitor the blood concentration of this product and adjust the whole blood concentration of this product so that it can be maintained within the range that can clinically play an immunosuppressive role without causing serious adverse reactions. It has been reported that if the whole blood trough concentration of this product measured before the next dose is about 100-200ng/ml, the above effect can be achieved. If adverse reactions occur, appropriate treatment should be given immediately, and the dosage of this product should be reduced or discontinued.

1. This product is contraindicated when there is a viral infection: such as chickenpox, herpes zoster, etc. 2. This product is contraindicated for those who are allergic to it.

Precautions for children: The dosage for children can be calculated according to or slightly higher than the adult dosage. Precautions for pregnancy and lactation: This product can enter breast milk. It may cause potential risks of adverse effects such as hypertension, nephrotoxicity, and malignant tumors to breastfeeding infants, so breastfeeding is not recommended during the use of this product. Precautions for the elderly: Elderly patients are prone to renal insufficiency, so this product should be used with caution.

1. This product can increase the plasma concentration of this product when used in combination with estrogen, androgen, cimetidine, diltiazem, erythromycin, ketoconazole, etc. Therefore, the liver and kidney toxicity of this product may be increased. Therefore, caution should be exercised when used in combination with the above drugs, and the patient's liver and kidney function and the blood concentration of this product should be monitored. 2. When used in combination with non-steroidal anti-inflammatory analgesics such as indomethacin, the risk of renal failure may increase. 3. When using this product, such as transfusing stored blood stored for more than 10 days or using this product in combination with potassium-sparing diuretics, high potassium-containing drugs, etc., blood potassium may increase. 4. Used in combination with liver enzyme inducers: Since it can induce liver microsomal enzymes, it increases the metabolism of this product. Therefore, the dosage of this product must be adjusted. 5. Used in combination with immunosuppressants such as adrenocortical hormones, azathioprine, chlorambucil, cyclophosphamide, etc. It may increase the risk of infection and lymphoproliferative diseases, so caution should be used. 6. When used in combination with lovastatin (a lipid-lowering drug) in patients with heart transplantation, the risk of rhabdomyolysis and acute renal failure may be increased. 7. When used in combination with drugs that can cause nephrotoxicity, the toxicity to the kidneys may be increased. If renal insufficiency occurs, the dosage of the drug should be reduced or the drug should be discontinued.

Protect from light, seal tightly and store in a cool place.

10 mg

24 months

North China Pharmaceutical Company.Ltd

• Founded in:

  1992-12-20

• Address:

  No. 388, Heping East Road, Shijiazhuang City

• Tax NO.:

  91130100104397700P

• Registered Funds:

  1,715,730,370 yuan

• Website:

  Log in to view

• Email:

  Log in to view